Skip to main content
. Author manuscript; available in PMC: 2022 Jan 3.
Published in final edited form as: Exp Hematol. 2021 May 21;99:1–11. doi: 10.1016/j.exphem.2021.05.004

Figure 2.

Figure 2

Upregulation of CALCRL is associated with relapse, leukemic stem cells, and poor outcome of AML, and CGRP signaling via CALCRL promotes therapy resistance and stem cell−related properties in AML. act=activity; DNR=daunorubicin; Dx=diagnosis; i.p.=intraperitoneal; Rel=relapse.